Is 13-valent pneumococcal conjugate vaccine ( PCV13 ) immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine ( PPSV23 ) : Results of a phase 3 study?
Children with SCD who were previously vaccinated with PPSV23 responded well to 1 PCV13 dose, and a second dose did not increase antibody response. PCV13 antibodies persisted above pre-vaccination levels for all serotypes 1 year after dose 2. Children with SCD may benefit from at least one dose of PCV13.
  Apple antimicrobial films could potentially be used in retail food packaging to reduce C. jejuni commonly present on food.